CAMBRIDGE, Mass., Oct. 15, 2015 - Mersana Therapeutics, Inc. today announced its presentation at World ADC San Diego, taking place October 19-22, 2015, at the Sheraton San Diego Hotel & Marina.

The presentation details are as follows:

Date: Wednesday, October 21, 2015
Time: 3:30 p.m. PT
Title: Fleximer ADCs: Advancing the Platforms Towards the Clinic
Conference Section: Pioneering New Developments to Fuel the ADCs of the Future
Presenter: Timothy Lowinger, Ph.D., Chief Scientific Officer, Mersana Therapeutics

World ADC San Diego provides a forum for sharing new antibody drug conjugate insights and data. For more information about the event, visit http://worldadc-usa.com/.

About Mersana Therapeutics
Mersana Therapeutics is advancing a proprietary pipeline of targeted oncology therapeutics leveraging its game-changing Fleximer® immunoconjugate technology. Mersana's first product candidate XMT-1522 has the potential to address significant unmet needs and improve patient outcomes in multiple oncology indications. Fleximer-based immunoconjugate molecules have been shown to have superior efficacy, including with targets previously considered not amenable to antibody-drug conjugate approaches. Mersana has collaborations utilizing Fleximer technology with Takeda, Merck KGaA, and Asana BioSciences. For more information, please visit www.mersana.com.

Media Contact
6 Degrees
Tony Plohoros
tplohoros@6degreespr.com
(908) 591-2839

Investors Contact
Stern Investor Relations, Inc.
Jesse Baumgartner
Jesse@sternir.com
(212) 362-1200